Skip to main content

Table 2 Comparison of results (group A and group B).

From: The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?

  Virus Suppression Therapy success
  Group A
Median
Viral load
Group B
Median Viral load
Mann-Whitney Group A
Success
Group B Success χ2
Baseline 26,950
(N = 10)
8,800
(N = 17)
P = 0.12 0%
(N = 10)
5.9%
(N = 17)
P = 0.998
Week 12 370
(N = 10)
< 50
(N = 15)
P = 0.07 40.0%
(N = 10)
66.7%
(N = 15)
P = 0.035
Week 24 4650
(N = 8)
< 50
(N = 13)
P = 0.16 37.5%
(N = 8)
69.2%
(N = 13)
P = 0.166
Week 48 3410
(N = 7)
< 50
(N = 13)
P = 0.19 42.9%
(N = 7)
53.8%
(N = 13)
P = 0.425
Week 96 15,045
(N = 6)
< 50
(N = 9)
P = 0.044 16.7%
(N = 6)
54.5%
(N = 9)
P = 0.002
  1. Comparison of results (group A and group B). Median viral loads and the therapy success rates illustrate a significantly better long-term suppression of HIV when SQV/ATV plus optimized backbone therapy is combined with a L76V-selecting drug. In bivariate analysis, these results were independent from slightly different baseline viral loads ( < 0,5log) between group A and B.